Research
Hormonal
If GLP-1RAs were made available for all people with obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 21,443.
Wider access to GLP-1RAs could lead to significant reductions in cancer cases among obese individuals.
StrongSupportsmedium confidence
If GLP-1RAs were made available for all people with obesity and 50 % of people with obesity moved into a lower BMI category, there was a simulated reduction in cumulative cancer cases of 21,443.
Why this rating
Based on the simulation model described in the abstract.
Source
Impact of GLP-1 receptor agonist-induced weight loss on 22 cancers in the next ten years using a Markov state-transition model – A UK weight and wellness cancer landscape analysis
Jiawen Dong et al. · Cancer Epidemiology · 2025
DOI 10.1016/j.canep.2025.102837
otherCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →